Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study
- PMID: 19095974
- PMCID: PMC2711777
- DOI: 10.1161/STROKEAHA.107.513259
Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study
Abstract
Background and purpose: Inflammation plays a critical role in the development of vascular disease, and increased levels of the inflammatory biomarkers, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), and high-sensitivity C-reactive protein (hs-CRP) have been shown to be associated with an increased risk for ischemic stroke.
Methods: In a prospective case-cohort (n=949) study in 12 762 apparently healthy, middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, we first examined whether Lp-PLA(2) and hs-CRP levels improved the area under the receiver operator characteristic curve (AUC) for 5-year ischemic stroke risk. We then examined how Lp-PLA(2) and hs-CRP levels altered classification of individuals into low-, intermediate-, or high-risk categories compared with traditional risk factors.
Results: In a model using traditional risk factors alone, the AUC adjusted for optimism was 0.732, whereas adding hs-CRP improved the AUC to 0.743, and adding Lp-PLA(2) significantly improved the AUC to 0.752. Addition of hs-CRP and Lp-PLA(2) together in the model improved the AUC to 0.761, and the addition of the interaction between Lp-PLA(2) and hs-CRP further significantly improved the AUC to 0.774. With the use of traditional risk factors to assess 5-year risk for ischemic stroke, 86% of participants were categorized as low risk (<2%); 11%, intermediate risk (2% to 5%); and 3%, high risk (>5%). The addition of hs-CRP, Lp-PLA(2), and their interaction to the model reclassified 4%, 39%, and 34% of the low-, intermediate- and high-risk categories, respectively.
Conclusions: Lp-PLA(2) and hs-CRP may be useful in individuals classified as intermediate risk for ischemic stroke by traditional risk factors.
Conflict of interest statement
Disclosures
C.M.B. has received honorarium from Merck and AstraZeneca. There are no other conflicts to report.
References
-
- Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126. - PubMed
-
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143. - PubMed
-
- Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565. - PubMed
-
- Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21–29. - PubMed
-
- Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD for the West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148–1155. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 HC055022/HC/NHLBI NIH HHS/United States
- N01 HC055016/HL/NHLBI NIH HHS/United States
- N01 HC055019/HL/NHLBI NIH HHS/United States
- N01-HC-55016/HC/NHLBI NIH HHS/United States
- N01 HC055018/HC/NHLBI NIH HHS/United States
- N01 HC055015/HL/NHLBI NIH HHS/United States
- N01-HC-55021/HC/NHLBI NIH HHS/United States
- N01-HC-55019/HC/NHLBI NIH HHS/United States
- N01-HC-55015/HC/NHLBI NIH HHS/United States
- N01-HC-55020/HC/NHLBI NIH HHS/United States
- N01 HC055015/HC/NHLBI NIH HHS/United States
- N01-HC-55018/HC/NHLBI NIH HHS/United States
- N01 HC055016/HC/NHLBI NIH HHS/United States
- N01-HC-55022/HC/NHLBI NIH HHS/United States
- N01 HC055021/HL/NHLBI NIH HHS/United States
- N01 HC055020/HL/NHLBI NIH HHS/United States
- N01 HC055019/HC/NHLBI NIH HHS/United States
- N01 HC055021/HC/NHLBI NIH HHS/United States
- N01 HC055018/HL/NHLBI NIH HHS/United States
- N01 HC055022/HL/NHLBI NIH HHS/United States
- N01 HC055020/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
